Joe Pantginnis

“So, Brian, you started the call by saying, you know, you're going to provide some background information, you know, behind the scenes and what have you. So, I'm really happy that you provided all of the manufacturing types of details.”

“First, Todd, I guess I'm going to approach ZOMA from the opposite end.”

“So, just curious now with this newly approved drug, what do you consider the important next steps? Of course, education is number one with regard to the readiness of physicians to include that new into the RX pipeline of these physicians.”

“So, Brian, I wanted to start with the ILT1 program, and I know the answer is probably going to be, you know, we just need to do the experiment, but you mentioned how you really need to scale up and be confident around your scale up around the baseline pluripotent cells.”

“So first on the phase two, so can you define the enrollment criteria a little better? Is it just the focus of time for diagnosis similar to now? And then also, as you said and as we believe, this is a very rigorous design that you're looking at, but it's from an ISP standpoint.”